Sarepta Stock Performance

News

Sarepta Shares Drop

Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug Administration (FDA) has imposed a clinical hold on several of its gene therapy programs targeting limb girdle muscular dystrophy (LGMD).

MarketWatch · 15h

FDA Places Sarepta's Investigational Gene-Therapy Trials on Hold Following Patient Death

The Food and Drug Administration placed a clinical hold on Sarepta Therapeutics' investigational gene-therapy clinical trials for limb-girdle muscular dystrophy, a group of genetic disorders that cause muscles to weaken and atrophy.

MyChesCo on MSN · 10h

FDA Shuts Down Sarepta Gene Therapy Trials After Three Deaths Linked to Liver Failure

The U.S. Food and Drug Administration on Friday placed Sarepta Therapeutics’ gene therapy trials for limb girdle muscular dystrophy on clinical hold following the deaths of three patients

10h

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

14h

Beware of SBET, WeBull, and Sarepta

Investors who bought WeBull (BULL) before last week gained 33.6%. However, after the market closed on Friday, July 18, the ...

13h

Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

Investing.com India9h

Sarepta shares hit as Mizuho, Leerink warn on FDA rift, credibility risk

Investing.com -- Sarepta Therapeutics came under pressure after two brokerages slashed their price targets and downgraded the stock, flagging mounting safety, regulatory, and credibility concerns ...

Sarepta: Finally, A Little Relief For Bulls; I Expect More

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

9hon MSN

Sarepta Stock Sinks. How Its Crisis Went From Bad to Worse.

Sarepta stock has tanked. Most investors don’t see the drugmaker’s executive management as credible following the failure to disclose a patient death, a BMO survey suggests.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results